PortfoliosLab logoPortfoliosLab logo
enGene Holdings Inc (ENGN)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
CA29286M1059
CUSIP
46429B226
IPO Date
Nov 1, 2023

Highlights

Market Cap
$458.06M
Enterprise Value
$432.31M
EPS (TTM)
-$0.20
Gross Profit (TTM)
-$407.00K
EBITDA (TTM)
-$58.87M
Year Range
$2.65 - $12.25
Target Price
$24.60
ROA (TTM)
-3.35%
ROE (TTM)
-4.01%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


enGene Holdings Inc

Often compared with ENGN:
ENGN vs. VUG

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in enGene Holdings Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

enGene Holdings Inc (ENGN) has returned -24.58% so far this year and 52.01% over the past 12 months.


enGene Holdings Inc

1D
10.19%
1M
-32.64%
YTD
-24.58%
6M
-0.29%
1Y
52.01%
3Y*
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Nov 1, 2023, ENGN's average daily return is +0.08%, while the average monthly return is +0.27%. At this rate, your investment would double in approximately 21.4 years.

Historically, 52% of months were positive and 48% were negative. The best month was Feb 2024 with a return of +88.1%, while the worst month was Nov 2023 at -61.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.

On a daily basis, ENGN closed higher 46% of trading days. The best single day was Feb 14, 2024 with a return of +116.5%, while the worst single day was Nov 3, 2023 at -31.0%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20265.54%6.09%-32.64%-24.58%
20250.75%-10.30%-25.46%-7.59%-7.25%-5.21%4.12%21.90%47.84%5.56%11.93%11.90%35.79%
2024-15.06%88.14%14.92%-6.19%-44.72%7.28%0.74%-26.53%-5.44%34.09%-2.26%-23.12%-27.95%
2023-61.70%20.50%-53.85%

Benchmark Metrics

enGene Holdings Inc has an annualized alpha of 7.10%, beta of 0.65, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 02, 2023.

  • This stock participated in 245.92% of S&P 500 Index downside but only -38.37% of its upside — more exposed to losses than it benefited from rallies.
  • Beta of 0.65 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
7.10%
Beta
0.65
0.01
Upside Capture
-38.37%
Downside Capture
245.92%

Return for Risk

Risk / Return Rank

ENGN ranks 65 for risk / return — better than 65% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


ENGN Risk / Return Rank: 6565
Overall Rank
ENGN Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
ENGN Sortino Ratio Rank: 6767
Sortino Ratio Rank
ENGN Omega Ratio Rank: 6565
Omega Ratio Rank
ENGN Calmar Ratio Rank: 6666
Calmar Ratio Rank
ENGN Martin Ratio Rank: 6666
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for enGene Holdings Inc (ENGN) and compare them to a chosen benchmark (S&P 500 Index).


ENGNBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.56

0.90

-0.33

Sortino ratio

Return per unit of downside risk

1.52

1.39

+0.13

Omega ratio

Gain probability vs. loss probability

1.19

1.21

-0.02

Calmar ratio

Return relative to maximum drawdown

1.19

1.40

-0.21

Martin ratio

Return relative to average drawdown

2.85

6.61

-3.75

Explore ENGN risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


enGene Holdings Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the enGene Holdings Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the enGene Holdings Inc was 85.60%, occurring on May 13, 2025. The portfolio has not yet recovered.

The current enGene Holdings Inc drawdown is 65.95%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-85.6%Nov 2, 2023382May 13, 2025

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of enGene Holdings Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how enGene Holdings Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ENGN in comparison with other companies in the Biotechnology industry. Currently, ENGN has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items